# ENDRA Life Sciences Inc.: overview NDRA · Nasdaq · CIK 1681682 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ndra.md) · [Financials](/companies/ndra/financials.md) · [Filings](/companies/ndra/filings.md) · [Insiders](/companies/ndra/insiders.md) Latest reported revenue: [$0](/filings/0001654954-21-003302.md) for Q4 FY2019, three months to 2019-12-31, from the 10-K filed Mar 25, 2021 (XBRL us-gaap:Revenues, accession 0001654954-21-003302). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.54)](/filings/0001213900-25-110887.md) | not reported | [(1.86)](/filings/0001213900-26-057680.md) | [(1.71)](/filings/0001213900-26-090027.md) | [(2.10)](/filings/0001213900-25-110887.md) | not reported | [(1.09)](/filings/0001213900-26-057680.md) | [0.06](/filings/0001213900-26-090027.md) | | Free cash flow | $k | [(1,657) d](/filings/0001213900-25-110887.md) | [(1,516) d](/filings/0001213900-26-037617.md) | [(1,310)](/filings/0001213900-26-057680.md) | [(1,114) d](/filings/0001213900-26-090027.md) | [(1,164) d](/filings/0001213900-25-110887.md) | [(1,612) d](/filings/0001213900-26-037617.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(2766.85)](/filings/0001654954-25-003937.md) | [(56.94)](/filings/0001213900-26-037617.md) | [(8.93)](/filings/0001213900-26-037617.md) | | Free cash flow | $m | [(11.2)](/filings/0001654954-23-003044.md) | [(13.0)](/filings/0001654954-24-003873.md) | [(9.6)](/filings/0001654954-25-003937.md) | [(7.4)](/filings/0001213900-26-037617.md) | [(5.2)](/filings/0001213900-26-037617.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ndra/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2024-08-27 | [UBS Group AG](/insiders/1610520.md) | 10% owner | Purchase (P) | 3,715 | $0.5523 | $2.1k | [Form 4](/filings/0001610520-24-000151.md) | | 2024-08-27 | [UBS Group AG](/insiders/1610520.md) | Market maker/broker-dealer | Purchase (P) | 0 | $0.00 | $0 | [Form 4/A](/filings/0001610520-24-000153.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Altium Capital Management LLC](/funds/1746382.md) | 2026-06-30 | $315.9k | 59,272 | | Added +7,372 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $159.5k | 29,924 | | New +29,924 | | [CITIZENS FINANCIAL GROUP INC/RI](/funds/759944.md) | 2026-06-30 | $151.4k | 28,400 | | New +28,400 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $79.5k | 14,910 | | Reduced −6,168 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $53.9k | 10,121 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $39.1k | 7,339 | | Added +4,523 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $18.9k | 3,546 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $362 | 68 | | Reduced −84 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $309 | 58 | | New +58 | | [NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO](/funds/1141802.md) | 2026-06-30 | $101 | 19 | | Unchanged | ## Recent filings [All 540 filings](/companies/ndra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 16:15 ET | [SCHEDULE 13D](/filings/0001477932-26-006128.md) | Ownership report, active investor | 0001477932-26-006128 | | 2026-10-01 | 17:18 ET | [8-K](/filings/0001213900-26-105899.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-105899 | | 2026-08-17 | 16:05 ET | [8-K](/filings/0001213900-26-090747.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090747 | | 2026-08-14 | 16:05 ET | [10-Q](/filings/0001213900-26-090027.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090027 | | 2026-07-09 | 06:08 ET | [8-K](/filings/0001213900-26-076526.md) | 8.01 Other events | 0001213900-26-076526 | | 2026-06-29 | 21:29 ET | [SCHEDULE 13D/A](/filings/0001213900-26-073318.md) | Ownership report, active investor, amended | 0001213900-26-073318 | | 2026-06-26 | 06:10 ET | [8-K](/filings/0001213900-26-072268.md) | 1.01 Entry into a material agreement; 5.01 Change in control; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-072268 | | 2026-06-25 | 09:37 ET | [8-K](/filings/0001213900-26-071804.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-071804 | | 2026-05-28 | 06:07 ET | [8-K](/filings/0001213900-26-061701.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-061701 | | 2026-05-15 | 16:01 ET | [10-Q](/filings/0001213900-26-057680.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057680 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037617.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1681682 - Tickers: NDRA - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:17 ET. No prices; not investment advice.